1.3M XNAS Volume
XNAS 18 Mar, 2025 12:02 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Gregory L. Weaver | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 13 Mar 2025 | 10,000 | 10,000 (0%) | 0% | 5.2 | 51,996 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Mar 2025 | 67,787 | 14,069 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Jerome B. Durso | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 69,800 | 69,800 | - | - | Stock Options (option to buy) | |
| Teri L Lawver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 69,800 | 69,800 | - | - | Stock Options (option to buy) | |
| Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 18,600 | 18,600 | - | - | Stock Options (option to buy) | |
| Raymond M. Jordt | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 5.18 per share. | 31 Jan 2025 | 2,614 | 34,902 (0%) | 0% | 5.2 | 13,541 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 18,950 | 18,950 | - | - | Restricted Stock Units | |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 16,545 | 0 | - | - | Restricted Stock Units | |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 26,775 | 53,550 | - | - | Restricted Stock Units | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 8,282 | 355,082 (2%) | 0% | 6.6 | 54,992 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 18,950 | 363,364 (2%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 7,231 | 344,414 (2%) | 0% | 6.6 | 48,014 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 16,545 | 351,645 (2%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 5.18 per share. | 30 Jan 2025 | 4,105 | 335,100 (2%) | 0% | 5.2 | 21,264 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 26,775 | 342,696 (2%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.00 per share. | 30 Jan 2025 | 11,701 | 330,995 (2%) | 0% | 7 | 81,907 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 7,775 | 7,775 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 9,275 | 62,921 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| M. Scot Roberts | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.00 per share. | 30 Jan 2025 | 2,709 | 60,212 (0%) | 0% | 7 | 18,963 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 5.18 per share. | 30 Jan 2025 | 3,184 | 63,396 (0%) | 0% | 5.2 | 16,493 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 6,166 | 69,562 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| M. Scot Roberts | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 1,801 | 67,761 (0%) | 0% | 6.6 | 11,959 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 7,775 | 75,536 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| M. Scot Roberts | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 2,316 | 73,220 (0%) | 0% | 6.6 | 15,378 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 9,275 | 18,550 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 6,166 | 0 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 5.18 per share. | 30 Jan 2025 | 1,905 | 72,732 (0%) | 0% | 5.2 | 9,868 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 6,166 | 78,898 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 2,109 | 76,789 (0%) | 0% | 6.6 | 14,004 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 7,775 | 7,775 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 6,166 | 0 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 9,275 | 18,550 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.64 per share. | 30 Jan 2025 | 2,708 | 81,856 (0%) | 0% | 6.6 | 17,981 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 7,775 | 84,564 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 9,275 | 74,000 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.00 per share. | 30 Jan 2025 | 3,173 | 70,827 (0%) | 0% | 7 | 22,211 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 477,500 | 477,500 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 164,800 | 164,800 | - | - | Restricted Stock Units | |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 42,050 | 334,078 (2%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.98 per share. | 25 Jan 2025 | 18,157 | 315,921 (2%) | 0% | 7.0 | 126,736 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 42,050 | 126,150 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 43,800 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 183,600 | 183,600 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 63,400 | 63,400 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 57,910 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| M. Scot Roberts | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.98 per share. | 25 Jan 2025 | 4,264 | 53,646 (0%) | 0% | 7.0 | 29,763 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.98 per share. | 25 Jan 2025 | 4,994 | 64,725 (0%) | 0% | 7.0 | 34,858 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 63,400 | 63,400 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 183,600 | 183,600 | - | - | Stock Options (option to buy) | |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 69,719 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 43,800 | - | - | Restricted Stock Units | |
| Raymond M. Jordt | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 63,400 | 63,400 | - | - | Restricted Stock Units | |
| Raymond M. Jordt | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.98 per share. | 25 Jan 2025 | 3,862 | 32,288 (0%) | 0% | 7.0 | 26,957 | Common Stock, par value $0.0001 |
| Raymond M. Jordt | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 43,800 | - | - | Restricted Stock Units | |
| Raymond M. Jordt | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2025 | 183,600 | 183,600 | - | - | Stock Options (option to buy) | |
| Raymond M. Jordt | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2025 | 14,600 | 36,150 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Raymond M. Jordt | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 9,375 | 24,035 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Raymond M. Jordt | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.21 per share. | 01 Jan 2025 | 2,485 | 21,550 (0%) | 0% | 7.2 | 17,917 | Common Stock, par value $0.0001 |
| Raymond M. Jordt | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 9,375 | 18,750 | - | - | Restricted Stock Units | |
| Mitchel Sayare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 34,900 | 34,900 | - | - | Stock Options (option to buy) | |
| John M. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 34,900 | 34,900 | - | - | Stock Options (option to buy) | |
| Wayne Pisano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 34,900 | 34,900 | - | - | Stock Options (option to buy) | |
| Diane K. Jorkasky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 34,900 | 34,900 | - | - | Stock Options (option to buy) | |
| Catherine Angell Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 34,900 | 34,900 | - | - | Stock Options (option to buy) | |
| Philip L. Hodges | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 34,900 | 34,900 | - | - | Stock Options (option to buy) | |
| Klaus O. Schafer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Sep 2024 | 34,900 | 34,900 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.60 per share. | 19 Aug 2024 | 20,000 | 49,785 (0%) | 0% | 2.6 | 52,000 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 20,000 | 0 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Sale of securities on an exchange or to another person at price $ 6.88 per share. | 19 Aug 2024 | 8,184 | 55,524 (0%) | 0% | 6.9 | 56,306 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 21,750 | 4,350 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 19 Aug 2024 | 21,750 | 63,708 (0%) | 0% | 2.5 | 54,375 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Sale of securities on an exchange or to another person at price $ 6.93 per share. | 19 Aug 2024 | 7,827 | 41,958 (0%) | 0% | 6.9 | 54,241 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 5.41 per share. | 31 Jul 2024 | 650 | 43,310 (0%) | 0% | 5.4 | 3,517 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 5.41 per share. | 31 Jul 2024 | 1,486 | 55,119 (0%) | 0% | 5.4 | 8,039 | Common Stock, par value $0.0001 |
| Raymond M. Jordt | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 5.41 per share. | 31 Jul 2024 | 917 | 14,660 (0%) | 0% | 5.4 | 4,961 | Common Stock, par value $0.0001 |
| Andrew Shutterly | Acting Chief Financial Officer | 31 Jul 2024 | 1,259 | 11,372 (0%) | 0% | 5.4 | 6,811 | Common Stock, par value $0.0001 | |
| Garg Vipin K. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 16,545 | 288,767 (1%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Scot Roberts M. | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 6,166 | 39,016 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Harris Scott | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.32 per share. | 01 Feb 2024 | 2,332 | 53,633 (0%) | 0% | 9.3 | 21,734 | Common Stock, par value $0.0001 |
| Roberts M. Scot | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.88 per share. | 01 Feb 2024 | 1,801 | 37,215 (0%) | 0% | 9.9 | 17,794 | Common Stock, par value $0.0001 |
| Scot M. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,775 | 44,990 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| M. Roberts Scot | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.32 per share. | 01 Feb 2024 | 2,330 | 42,660 (0%) | 0% | 9.3 | 21,716 | Common Stock, par value $0.0001 |
| Harris Scott Matthew | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,775 | 55,965 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| K. Garg Vipin | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.32 per share. | 01 Feb 2024 | 8,376 | 292,028 (1%) | 0% | 9.3 | 78,064 | Common Stock, par value $0.0001 |
| Harris Scott Matthew | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,775 | 15,550 | - | - | Restricted Stock Units | |
| Harris Scott Matthew | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 6,166 | 6,166 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 6,166 | 6,166 | - | - | Restricted Stock Units | |
| Roberts Scot M. | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,775 | 15,550 | - | - | Restricted Stock Units | |
| Garg Vipin K. | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 16,545 | 16,545 | - | - | Restricted Stock Units | |
| Matthew Harris Scott | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.88 per share. | 01 Feb 2024 | 1,801 | 48,190 (0%) | 0% | 9.9 | 17,794 | Common Stock, par value $0.0001 |
| K. Vipin Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 18,950 | 300,404 (1%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Harris Scott | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 6,166 | 49,991 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| K. Garg Vipin | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 18,950 | 37,900 | - | - | Restricted Stock Units | |
| K. Garg Vipin | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.88 per share. | 01 Feb 2024 | 7,313 | 281,454 (1%) | 0% | 9.9 | 72,252 | Common Stock, par value $0.0001 |
| M. Raymond Jordt | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 2.69 per share. | 31 Jan 2024 | 5,030 | 13,743 (0%) | 0% | 2.7 | 13,531 | Common Stock, par value $0.0001 |
| Richard Eisenstadt I. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 42,566 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| M. Scot Roberts | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.80 per share. | 30 Jan 2024 | 2,709 | 26,990 (0%) | 0% | 9.8 | 26,548 | Common Stock, par value $0.0001 |
| Richard I. Eisenstadt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 2.69 per share. | 30 Jan 2024 | 4,621 | 45,012 (0%) | 0% | 2.7 | 12,430 | Common Stock, par value $0.0001 |
| Garg Vipin K. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.69 per share. | 30 Jan 2024 | 7,889 | 272,222 (1%) | 0% | 2.7 | 21,221 | Common Stock, par value $0.0001 |
| Scot M. Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 2.69 per share. | 30 Jan 2024 | 5,860 | 32,850 (0%) | 0% | 2.7 | 15,763 | Common Stock, par value $0.0001 |
| Vipin Garg K. | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.80 per share. | 30 Jan 2024 | 11,697 | 264,333 (1%) | 0% | 9.8 | 114,631 | Common Stock, par value $0.0001 |
| Scot M. Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 29,699 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 43,277 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.80 per share. | 30 Jan 2024 | 2,709 | 40,568 (0%) | 0% | 9.8 | 26,548 | Common Stock, par value $0.0001 |
| Richard Eisenstadt I. | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.80 per share. | 30 Jan 2024 | 2,175 | 40,391 (0%) | 0% | 9.8 | 21,315 | Common Stock, par value $0.0001 |
| Scot Roberts M. | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 27,825 | - | - | Restricted Stock Units | |
| Scott Matthew Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.69 per share. | 30 Jan 2024 | 3,257 | 43,825 (0%) | 0% | 2.7 | 8,761 | Common Stock, par value $0.0001 |
| Matthew Harris Scott | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 27,825 | - | - | Restricted Stock Units | |
| Garg K. Vipin | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 26,775 | 80,325 | - | - | Restricted Stock Units | |
| I. Eisenstadt Richard | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 9,275 | 27,825 | - | - | Restricted Stock Units | |
| K. Garg Vipin | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 26,775 | 276,030 (1%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Raymond Jordt M. | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 58,400 | 58,400 | - | - | Restricted Stock Units | |
| Raymond Jordt M. | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 163,200 | 163,200 | - | - | Stock Options (option to buy) | |
| Harris Scott Matthew | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 58,400 | 58,400 | - | - | Restricted Stock Units | |
| Richard I. Eisenstadt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 163,200 | 163,200 | - | - | Stock Options (option to buy) | |
| I. Richard Eisenstadt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 58,400 | 58,400 | - | - | Restricted Stock Units | |
| M. Roberts Scot | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 163,200 | 163,200 | - | - | Stock Options (option to buy) | |
| K. Vipin Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 470,000 | 470,000 | - | - | Stock Options (option to buy) | |
| Garg K. Vipin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 168,200 | 168,200 | - | - | Restricted Stock Units | |
| Scot Roberts M. | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 58,400 | 58,400 | - | - | Restricted Stock Units | |
| Harris Scott Matthew | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2024 | 163,200 | 163,200 | - | - | Stock Options (option to buy) | |
| Jordt M. Raymond | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 9,375 | 28,125 | - | - | Restricted Stock Units | |
| Raymond Jordt M. | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.25 per share. | 01 Jan 2024 | 2,503 | 8,704 (0%) | 0% | 11.3 | 28,159 | Common Stock, par value $0.0001 |
| Jordt Raymond M. | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 9,375 | 11,207 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| I. Richard Eisenstadt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2023 | 12,500 | 36,335 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| I. Richard Eisenstadt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2023 | 12,500 | 25,000 | - | - | Restricted Stock Units | |
| I. Eisenstadt Richard | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.25 per share. | 29 Dec 2023 | 3,044 | 33,291 (0%) | 0% | 11.3 | 34,245 | Common Stock, par value $0.0001 |
| Schafer Klaus O. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| John Gill M. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| Angell Sohn Catherine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| Jorkasky Diane K. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| Pisano Wayne | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| Mitchel Sayare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| Drutz J. David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| Philip L. Hodges | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2023 | 26,100 | 26,100 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Purchase of securities on an exchange or from another person at price $ 2.88 per share. | 15 Aug 2023 | 300 | 29,785 (0%) | 0% | 2.9 | 863 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.81 per share. | 31 Jul 2023 | 126 | 249,255 (1%) | 0% | 2.8 | 354 | Common Stock, par value $0.0001 |
| Richard I. Eisenstadt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 2.81 per share. | 31 Jul 2023 | 1,825 | 23,835 (0%) | 0% | 2.8 | 5,128 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 2.81 per share. | 31 Jul 2023 | 568 | 20,424 (0%) | 0% | 2.8 | 1,596 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.81 per share. | 31 Jul 2023 | 691 | 34,002 (0%) | 0% | 2.8 | 1,942 | Common Stock, par value $0.0001 |
| Raymond M. Jordt | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 2.81 per share. | 31 Jul 2023 | 1,832 | 1,832 (0%) | 0% | 2.8 | 5,148 | Common Stock, par value $0.0001 |
| Richard I. Eisenstadt | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.31 per share. | 24 Mar 2023 | 10,000 | 22,010 (0%) | 0% | 4.3 | 43,140 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Purchase of securities on an exchange or from another person at price $ 4.27 per share. | 23 Mar 2023 | 9,000 | 29,484 (0%) | 0% | 4.3 | 38,430 | Common Stock, par value $0.0001 |
| Catherine A. Sohn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Mar 2023 | 47,000 | 47,000 | - | - | Stock Options (option to buy) | |
| Matthew Scott Harris | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 4.22 per share. | 23 Mar 2023 | 10,000 | 33,311 (0%) | 0% | 4.2 | 42,200 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 18,950 | 257,551 (1%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.04 per share. | 02 Feb 2023 | 8,422 | 249,129 (1%) | 0% | 15.0 | 126,667 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 18,950 | 56,850 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 7,775 | 22,231 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 7,775 | 23,325 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.04 per share. | 02 Feb 2023 | 2,375 | 19,856 (0%) | 0% | 15.0 | 35,720 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.04 per share. | 02 Feb 2023 | 2,364 | 23,311 (0%) | 0% | 15.0 | 35,555 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 7,775 | 23,325 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 7,775 | 25,675 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 16,546 | 33,090 | - | - | Restricted Stock Units | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 10.21 per share. | 31 Jan 2023 | 1,938 | 229,713 (1%) | 0% | 10.2 | 19,784 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 16,546 | 246,259 (1%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.78 per share. | 31 Jan 2023 | 7,658 | 238,601 (1%) | 0% | 13.8 | 105,527 | Common Stock, par value $0.0001 |
| Richard I. Eisenstadt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 10.21 per share. | 31 Jan 2023 | 1,172 | 12,010 (0%) | 0% | 10.2 | 11,964 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 10.21 per share. | 31 Jan 2023 | 1,436 | 10,473 (0%) | 0% | 10.2 | 14,659 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 6,166 | 12,332 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.78 per share. | 31 Jan 2023 | 2,183 | 14,456 (0%) | 0% | 13.8 | 30,082 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 6,166 | 16,639 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 10.21 per share. | 31 Jan 2023 | 1,296 | 13,917 (0%) | 0% | 10.2 | 13,230 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 6,166 | 20,083 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.78 per share. | 31 Jan 2023 | 2,183 | 17,900 (0%) | 0% | 13.8 | 30,082 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 6,166 | 12,332 | - | - | Restricted Stock Units | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 302,900 | 302,900 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 107,100 | 107,100 | - | - | Restricted Stock Units | |
| Richard I. Eisenstadt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 37,100 | 37,100 | - | - | Restricted Stock Units | |
| Richard I. Eisenstadt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 105,000 | 105,000 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 37,100 | 37,100 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 105,000 | 105,000 | - | - | Stock Options (option to buy) | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 37,100 | 37,100 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2023 | 105,000 | 105,000 | - | - | Stock Options (option to buy) | |
| Raymond M. Jordt | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 125,000 | 125,000 | - | - | Stock Options (option to buy) | |
| Raymond M. Jordt | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 37,500 | 37,500 | - | - | Restricted Stock Units | |
| Richard I. Eisenstadt | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.45 per share. | 31 Dec 2022 | 3,028 | 10,838 (0%) | 0% | 16.5 | 49,811 | Common Stock, par value $0.0001 |
| Richard I. Eisenstadt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 12,500 | 37,500 | - | - | Restricted Stock Units | |
| Richard I. Eisenstadt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 12,500 | 13,866 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Wayne Pisano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.60 per share. | 22 Dec 2022 | 20,000 | 28,498 (0%) | 0% | 2.6 | 52,000 | Common Stock, par value $0.0001 |
| Wayne Pisano | Director | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 22 Dec 2022 | 20,000 | 8,498 (0%) | 0% | 15.0 | 300,268 | Common Stock, par value $0.0001 |
| Wayne Pisano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2022 | 20,000 | 0 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.95 per share. | 30 Nov 2022 | 3,007 | 227,775 (1%) | 0% | 10.0 | 29,920 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.40 per share. | 18 Nov 2022 | 139 | 20,151 (0%) | 0% | 2.4 | 334 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2022 | 139 | 0 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.77 per share. | 30 Oct 2022 | 3,007 | 230,782 (1%) | 0% | 12.8 | 38,399 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.77 per share. | 30 Sep 2022 | 3,008 | 233,789 (1%) | 0% | 12.8 | 38,412 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 20.02 per share. | 30 Aug 2022 | 20,000 | 236,797 (1%) | 0% | 20.0 | 400,322 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.94 per share. | 30 Aug 2022 | 3,007 | 256,797 (1%) | 0% | 18.9 | 56,953 | Common Stock, par value $0.0001 |
| John M. Gill | Director | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 12 Aug 2022 | 2,714 | 2,771 (0%) | 0% | 15 | 40,710 | Common Stock, par value $0.0001 |
| Richard I. Eisenstadt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jul 2022 | 1,366 | 1,366 (0%) | 0% | 6.9 | 9,371 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jul 2022 | 732 | 9,037 (0%) | 0% | 6.9 | 5,022 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jul 2022 | 1,076 | 12,621 (0%) | 0% | 6.9 | 7,381 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.01 per share. | 30 Jul 2022 | 3,007 | 274,804 (1%) | 0% | 12.0 | 36,114 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.60 per share. | 01 Jul 2022 | 4,019 | 21,719 (0%) | 0% | 2.6 | 10,449 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 787 | 14,250 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 22,963 | 15,037 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 4,019 | 8,750 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 01 Jul 2022 | 10,182 | 8,305 (0%) | 0% | 12 | 122,184 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.95 per share. | 01 Jul 2022 | 787 | 18,487 (0%) | 0% | 3.0 | 2,322 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 01 Jul 2022 | 26,982 | 17,700 (0%) | 0% | 12 | 323,784 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.95 per share. | 01 Jul 2022 | 22,963 | 44,682 (0%) | 0% | 3.0 | 67,741 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.70 per share. | 30 Jun 2022 | 3,007 | 277,811 (1%) | 0% | 11.7 | 35,182 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 29 Jun 2022 | 5,462 | 17,700 (0%) | 0% | 12.0 | 65,546 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2022 | 5,462 | 12,769 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.60 per share. | 29 Jun 2022 | 5,462 | 23,162 (0%) | 0% | 2.6 | 14,201 | Common Stock, par value $0.0001 |
| Diane K. Jorkasky | Director | Sale of securities on an exchange or to another person at price $ 11.75 per share. | 27 Jun 2022 | 17,610 | 0 (0%) | 0% | 11.8 | 206,944 | Common Stock, par value $0.0001 |
| Diane K. Jorkasky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.15 per share. | 27 Jun 2022 | 17,610 | 17,610 (0%) | 0% | 3.2 | 55,472 | Common Stock, par value $0.0001 |
| Diane K. Jorkasky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2022 | 17,610 | 22,390 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2022 | 11,769 | 18,231 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.92 per share. | 27 Jun 2022 | 25,583 | 43,283 (0%) | 0% | 1.9 | 49,153 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.60 per share. | 27 Jun 2022 | 11,769 | 55,052 (0%) | 0% | 2.6 | 30,599 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 27 Jun 2022 | 37,352 | 17,700 (0%) | 0% | 12.0 | 448,254 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jun 2022 | 25,583 | 35,817 | - | - | Stock Options (option to buy) | |
| Klaus O. Schafer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.40 per share. | 20 Jun 2022 | 60 | 8,960 (0%) | 0% | 2.4 | 144 | Common Stock, par value $0.0001 |
| Klaus O. Schafer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2022 | 159 | 0 | - | - | Stock Options (option to buy) | |
| Klaus O. Schafer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2022 | 60 | 0 | - | - | Stock Options (option to buy) | |
| Klaus O. Schafer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.40 per share. | 20 Jun 2022 | 60 | 9,179 (0%) | 0% | 2.4 | 144 | Common Stock, par value $0.0001 |
| Klaus O. Schafer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.40 per share. | 20 Jun 2022 | 159 | 9,119 (0%) | 0% | 2.4 | 382 | Common Stock, par value $0.0001 |
| Klaus O. Schafer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2022 | 60 | 0 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Purchase of securities on an exchange or from another person at price $ 8.00 per share. | 15 Jun 2022 | 1,000 | 20,012 (0%) | 0% | 8 | 8,000 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.03 per share. | 30 May 2022 | 3,008 | 280,818 (1%) | 0% | 5.0 | 15,130 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Purchase of securities on an exchange or from another person at price $ 4.50 per share. | 24 May 2022 | 1,200 | 19,012 (0%) | 0% | 4.5 | 5,400 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.52 per share. | 30 Apr 2022 | 3,008 | 283,826 (1%) | 0% | 4.5 | 13,596 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.05 per share. | 30 Mar 2022 | 3,007 | 286,834 (1%) | 0% | 6.0 | 18,192 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.41 per share. | 28 Feb 2022 | 3,007 | 289,841 (1%) | 0% | 7.4 | 22,282 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.52 per share. | 28 Feb 2022 | 30,000 | 11,545 (0%) | 0% | 7.5 | 225,600 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 30,000 | 31,400 | - | - | Stock Options (option to buy) | |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.92 per share. | 28 Feb 2022 | 30,000 | 41,545 (0%) | 0% | 1.9 | 57,639 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 16,545 | 300,503 (1%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jan 2022 | 2,757 | 283,958 (1%) | 0% | 6.9 | 18,913 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 75,800 | 75,800 | - | - | Restricted Stock Units | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 223,000 | 223,000 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 16,545 | 49,636 | - | - | Restricted Stock Units | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.98 per share. | 31 Jan 2022 | 7,655 | 292,848 (1%) | 0% | 8.0 | 61,087 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 6,166 | 18,498 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.98 per share. | 31 Jan 2022 | 2,183 | 17,700 (0%) | 0% | 8.0 | 17,420 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 6,166 | 19,883 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jan 2022 | 2,106 | 13,717 (0%) | 0% | 6.9 | 14,447 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 31,100 | 31,100 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 91,600 | 91,600 | - | - | Stock Options (option to buy) | |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 6,166 | 18,498 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.98 per share. | 31 Jan 2022 | 2,183 | 11,545 (0%) | 0% | 8.0 | 17,420 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2022 | 6,166 | 13,728 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 6.86 per share. | 31 Jan 2022 | 1,800 | 7,562 (0%) | 0% | 6.9 | 12,348 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 31,100 | 31,100 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 91,600 | 91,600 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.20 per share. | 30 Jan 2022 | 2,355 | 281,201 (1%) | 0% | 7.2 | 16,956 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 139 | 139 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 139 | 139 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 139 | 0 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.40 per share. | 14 Dec 2021 | 139 | 17,812 (0%) | 0% | 2.4 | 334 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.49 per share. | 30 Nov 2021 | 3,007 | 286,563 (1%) | 0% | 10.5 | 31,543 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.80 per share. | 30 Oct 2021 | 3,007 | 289,570 (1%) | 0% | 10.8 | 32,476 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.31 per share. | 30 Sep 2021 | 3,007 | 292,577 (1%) | 0% | 11.3 | 34,009 | Common Stock, par value $0.0001 |
| Diane K. Jorkasky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2021 | 24,100 | 24,100 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.09 per share. | 30 Aug 2021 | 3,008 | 295,584 (1%) | 0% | 14.1 | 42,383 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 7.71 per share. | 31 Jul 2021 | 1,750 | 11,611 (0%) | 0% | 7.7 | 13,492 | Common Stock, par value $0.0001 |
| William Brown | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 7.71 per share. | 31 Jul 2021 | 803 | 17,721 (0%) | 0% | 7.7 | 6,191 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 7.71 per share. | 31 Jul 2021 | 725 | 5,762 (0%) | 0% | 7.7 | 5,589 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.07 per share. | 30 Jul 2021 | 3,007 | 298,592 (1%) | 0% | 9.1 | 27,273 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.85 per share. | 30 Jun 2021 | 3,007 | 301,599 (1%) | 0% | 9.9 | 29,619 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.65 per share. | 30 May 2021 | 2,577 | 304,606 (1%) | 0% | 12.6 | 32,599 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.47 per share. | 30 Apr 2021 | 1,999 | 307,183 (2%) | 0% | 14.5 | 28,926 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.55 per share. | 30 Mar 2021 | 1,998 | 309,182 (2%) | 0% | 13.6 | 27,073 | Common Stock, par value $0.0001 |
| Philip L. Hodges | Director | Sale of securities on an exchange or to another person at price $ 16.08 per share. | 01 Mar 2021 | 6,000 | 8,731 (0%) | 0% | 16.1 | 96,480 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.94 per share. | 28 Feb 2021 | 1,998 | 311,180 (2%) | 0% | 15.9 | 31,848 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 12.14 per share. | 31 Jan 2021 | 1,055 | 313,178 (2%) | 0% | 12.1 | 12,808 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 66,181 | 66,181 | - | - | Restricted Stock Units | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 241,500 | 241,500 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 12.14 per share. | 31 Jan 2021 | 467 | 9,861 (0%) | 0% | 12.1 | 5,669 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 24,664 | 24,664 | - | - | Restricted Stock Units | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 90,000 | 90,000 | - | - | Stock Options (option to buy) | |
| William Brown | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.14 per share. | 31 Jan 2021 | 937 | 16,918 (0%) | 0% | 12.1 | 11,375 | Common Stock, par value $0.0001 |
| William Brown | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 24,664 | 24,664 | - | - | Restricted Stock Units | |
| William Brown | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 90,000 | 90,000 | - | - | Stock Options (option to buy) | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 12.14 per share. | 31 Jan 2021 | 968 | 5,037 (0%) | 0% | 12.1 | 11,752 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 24,664 | 24,664 | - | - | Restricted Stock Units | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 90,000 | 90,000 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.28 per share. | 30 Jan 2021 | 2,353 | 312,123 (2%) | 0% | 14.3 | 33,601 | Common Stock, par value $0.0001 |
| Klaus O. Schafer | Director | Purchase of securities on an exchange or from another person at price $ 11.99 per share. | 10 Dec 2020 | 2,000 | 8,900 (0%) | 0% | 12.0 | 23,980 | Common Stock, par value $0.0001 |
| John M. Gill | Director | Sale of securities on an exchange or to another person at price $ 11.92 per share. | 30 Nov 2020 | 8,425 | 11,199 (0%) | 0% | 11.9 | 100,426 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.23 per share. | 30 Nov 2020 | 2,243 | 317,501 (2%) | 0% | 12.2 | 27,432 | Common Stock, par value $0.0001 |
| Philip L. Hodges | Director | Sale of securities on an exchange or to another person at price $ 13.54 per share. | 30 Nov 2020 | 1,227 | 0 (0%) | 0% | 13.5 | 16,614 | Common Stock, par value $0.0001 |
| Philip L. Hodges | Director | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 30 Nov 2020 | 2,500 | 14,731 (0%) | 0% | 12 | 30,000 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2020 | 60 | 0 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.40 per share. | 13 Nov 2020 | 60 | 17,603 (0%) | 0% | 2.4 | 144 | Common Stock, par value $0.0001 |
| Wayne Pisano | Director | Sale of securities on an exchange or to another person at price $ 9.90 per share. | 12 Nov 2020 | 10,352 | 8,498 (0%) | 0% | 9.9 | 102,485 | Common Stock, par value $0.0001 |
| Klaus O. Schafer | Director | Sale of securities on an exchange or to another person at price $ 9.91 per share. | 12 Nov 2020 | 10,150 | 6,900 (0%) | 0% | 9.9 | 100,587 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Director | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 12 Nov 2020 | 4,015 | 4,069 (0%) | 0% | 10.0 | 40,230 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.45 per share. | 30 Oct 2020 | 2,015 | 319,744 (2%) | 0% | 11.5 | 23,072 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.20 per share. | 30 Sep 2020 | 2,015 | 321,759 (2%) | 0% | 13.2 | 26,598 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 25,500 | 25,500 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 0 | - | - | Restricted Stock Units ("RSUs") | |
| David J. Drutz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 17,543 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Mitchel Sayare | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 25,275 | 26,363 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Mitchel Sayare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 25,500 | 25,500 | - | - | Stock Options (option to buy) | |
| Mitchel Sayare | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 25,275 | 0 | - | - | Restricted Stock Units ("RSUs") | |
| John M. Gill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 19,624 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| John M. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 25,500 | 25,500 | - | - | Stock Options (option to buy) | |
| John M. Gill | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 0 | - | - | Restricted Stock Units ("RSUs") | |
| Wayne Pisano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 25,500 | 25,500 | - | - | Stock Options (option to buy) | |
| Wayne Pisano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 18,850 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Wayne Pisano | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 0 | - | - | Restricted Stock Units ("RSUs") | |
| Diane K. Jorkasky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 9,500 | 9,500 | - | - | Stock Options (option to buy) | |
| Philip L. Hodges | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 25,500 | 25,500 | - | - | Stock Options (option to buy) | |
| Philip L. Hodges | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 36,306 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Philip L. Hodges | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 0 | - | - | Restricted Stock Units ("RSUs") | |
| Klaus O. Schafer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 0 | - | - | Restricted Stock Units ("RSUs") | |
| Klaus O. Schafer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 25,500 | 25,500 | - | - | Stock Options (option to buy) | |
| Klaus O. Schafer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2020 | 16,850 | 17,050 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.62 per share. | 30 Aug 2020 | 2,015 | 323,774 (2%) | 0% | 17.6 | 35,504 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 31 Jul 2020 | 11,674 | 325,789 (2%) | 0% | 1.5 | 17,044 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 31 Jul 2020 | 3,859 | 9,394 (0%) | 0% | 1.5 | 5,634 | Common Stock, par value $0.0001 |
| William Brown | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 31 Jul 2020 | 7,920 | 15,981 (0%) | 0% | 1.5 | 11,563 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 31 Jul 2020 | 8,084 | 8,084 (0%) | 0% | 1.5 | 11,803 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.06 per share. | 30 Jul 2020 | 2,015 | 314,115 (2%) | 0% | 26.1 | 52,511 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.71 per share. | 30 Jun 2020 | 2,015 | 316,130 (2%) | 0% | 10.7 | 21,581 | Common Stock, par value $0.0001 |
| David J. Drutz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 16,850 | 16,850 | - | - | Restricted Stock Units ("RSUs") | |
| Mitchel Sayare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 25,275 | 25,275 | - | - | Restricted Stock Units ("RSUs") | |
| John M. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 16,850 | 16,850 | - | - | Restricted Stock Units ("RSUs") | |
| Wayne Pisano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 16,850 | 16,850 | - | - | Restricted Stock Units ("RSUs") | |
| Philip L. Hodges | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 16,850 | 16,850 | - | - | Restricted Stock Units ("RSUs") | |
| Klaus O. Schafer | Director | 25 Jun 2020 | 16,850 | 16,850 | - | - | Restricted Stock Units ("RSUs") | ||
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.28 per share. | 30 May 2020 | 2,015 | 318,145 (2%) | 0% | 9.3 | 18,699 | Common Stock, par value $0.0001 |
| Diane K. Jorkasky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2020 | 40,000 | 40,000 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.05 per share. | 30 Apr 2020 | 2,015 | 320,160 (2%) | 0% | 3.1 | 6,146 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.02 per share. | 31 Mar 2020 | 2,016 | 322,175 (2%) | 0% | 3.0 | 6,088 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 29 Feb 2020 | 2,015 | 324,191 (2%) | 0% | 3.7 | 7,456 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 31 Jan 2020 | 11,289 | 326,206 (2%) | 0% | 1.5 | 16,482 | Common Stock, par value $0.0001 |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 31 Jan 2020 | 3,698 | 5,535 (0%) | 0% | 1.5 | 5,399 | Common Stock, par value $0.0001 |
| William Brown | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 31 Jan 2020 | 8,061 | 8,061 (0%) | 0% | 1.5 | 11,769 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.77 per share. | 30 Jan 2020 | 2,015 | 314,917 (2%) | 0% | 1.8 | 3,567 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 149,500 | 149,500 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 61,400 | 61,400 | - | - | Stock Options (option to buy) | |
| William Brown | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 61,400 | 61,400 | - | - | Stock Options (option to buy) | |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 61,400 | 61,400 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.80 per share. | 30 Dec 2019 | 1,999 | 316,932 (2%) | 0% | 1.8 | 3,598 | Common Stock, par value $0.0001 |
| Vipin K. Garg | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.82 per share. | 30 Nov 2019 | 23,976 | 318,931 (2%) | 0% | 1.8 | 43,636 | Common Stock, par value $0.0001 |
| Matthew Scott Harris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2019 | 107,000 | 107,000 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 2.10 per share. | 05 Sep 2019 | 20,000 | 342,907 (2%) | 0% | 2.1 | 42,000 | Common Stock, par value $0.0001 |
| Sybil Tasker | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| William Brown | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2019 | 50,000 | 50,000 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2019 | 38,000 | 38,000 | - | - | Stock Options (option to buy) | |
| Sybil Tasker | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2019 | 38,000 | 38,000 | - | - | Stock Options (option to buy) | |
| David J. Drutz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| Mitchel Sayare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 30,000 | 30,000 | - | - | Stock Options (option to buy) | |
| John M. Gill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| Wayne Pisano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 30,000 | 30,000 | - | - | Stock Options (option to buy) | |
| Sybil Tasker | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 30,000 | 30,000 | - | - | Stock Options (option to buy) | |
| Philip L. Hodges | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| Klaus O. Schafer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| William Brown | Acting Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 30,000 | 30,000 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2018 | 322,907 | 322,907 (3%) | 3% | 0 | Common Stock, par value $0.0001 | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2018 | 211,486 | 211,486 | - | - | Stock Options (option to buy) | |
| Vipin K. Garg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2018 | 111,421 | 111,421 | - | - | Stock Options (option to buy) | |
| Wayne Pisano | None | Purchase of securities on an exchange or from another person at price $ 4.59 per share. | 09 Oct 2018 | 2,000 | 2,000 (0%) | 0% | 4.6 | 9,180 | Common Stock, par value $0.0001 |
| William J. Enright | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.51 per share. | 25 May 2018 | 1,300 | 365,839 (1%) | 0% | 0.5 | 660 | Common Stock, par value $0.0001 |
| William J. Enright | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2018 | 103,158 | 103,158 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2018 | 55,120 | 0 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2018 | 50,016 | 50,016 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.08 per share. | 21 May 2018 | 55,120 | 55,120 (0%) | 0% | 0.1 | 4,410 | Common Stock, par value $0.0001 |
| Sybil Tasker | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2018 | 50,016 | 50,016 | - | - | Stock Options (option to buy) | |
| Mitchel Sayare | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2018 | 35,000 | 35,000 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2018 | 183,347 | 0 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.08 per share. | 02 Jan 2018 | 183,347 | 364,511 (2%) | 1% | 0.1 | 14,668 | Common Stock, par value $0.0001 |
| Mitchel Sayare | None | Purchase of securities on an exchange or from another person at price $ 1.95 per share. | 29 Dec 2017 | 5,100 | 32,650 (0%) | 0% | 2.0 | 9,963 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.93 per share. | 28 Dec 2017 | 38,699 | 589,453 (3%) | 0% | 1.9 | 74,778 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.92 per share. | 28 Dec 2017 | 58,711 | 550,754 (3%) | 0% | 1.9 | 112,672 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.61 per share. | 22 Dec 2017 | 17,982 | 362,895 (2%) | 0% | 1.6 | 28,877 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.81 per share. | 22 Dec 2017 | 51,442 | 414,337 (2%) | 0% | 1.8 | 93,269 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.77 per share. | 22 Dec 2017 | 27,706 | 492,043 (3%) | 0% | 1.8 | 49,040 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.76 per share. | 22 Dec 2017 | 50,000 | 464,337 (2%) | 0% | 1.8 | 88,170 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.74 per share. | 06 Dec 2017 | 7,639 | 344,913 (2%) | 0% | 1.7 | 13,308 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.80 per share. | 06 Dec 2017 | 16,106 | 337,274 (2%) | 0% | 1.8 | 28,996 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.81 per share. | 01 Dec 2017 | 7,300 | 307,673 (1%) | 0% | 1.8 | 13,195 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.78 per share. | 01 Dec 2017 | 13,495 | 321,168 (2%) | 0% | 1.8 | 23,987 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.80 per share. | 01 Dec 2017 | 5,215 | 300,373 (1%) | 0% | 1.8 | 9,405 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.94 per share. | 28 Nov 2017 | 7,942 | 282,180 (1%) | 0% | 1.9 | 15,377 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.84 per share. | 28 Nov 2017 | 12,978 | 295,158 (1%) | 0% | 1.8 | 23,816 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 1.97 per share. | 28 Nov 2017 | 12,395 | 274,238 (1%) | 0% | 2.0 | 24,445 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.00 per share. | 22 Nov 2017 | 10,042 | 261,843 (1%) | 0% | 2.0 | 20,060 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.02 per share. | 22 Nov 2017 | 6,505 | 251,801 (1%) | 0% | 2.0 | 13,162 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.10 per share. | 22 Nov 2017 | 5,261 | 245,296 (1%) | 0% | 2.1 | 11,061 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.07 per share. | 17 Nov 2017 | 4,800 | 232,799 (1%) | 0% | 2.1 | 9,958 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.12 per share. | 17 Nov 2017 | 6,295 | 227,999 (1%) | 0% | 2.1 | 13,352 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.06 per share. | 17 Nov 2017 | 7,236 | 240,035 (1%) | 0% | 2.1 | 14,905 | Common Stock, par value $0.0001 |
| David J. Drutz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2017 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| Derace L. Schaffer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2017 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| Mitchel Sayare | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2017 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| John M. Gill | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2017 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| Philip L. Hodges | None | Other type of transaction at price $ 0.00 per share. | 13 Oct 2017 | 1,278,471 | 0 (0%) | 8% | 0 | Common Stock, par value $0.0001 | |
| Philip L. Hodges | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2017 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| Klaus O. Schafer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2017 | 20,000 | 20,000 | - | - | Stock Options (option to buy) | |
| Elizabeth Czerepak | CFO and EVP Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 62,500 | 62,500 | - | - | Stock Options (option to buy) | |
| Elizabeth Czerepak | CFO and EVP Corp. Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 62,500 | 62,500 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 125,000 | 125,000 | - | - | Stock Options (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 50,000 | 50,000 | - | - | Stock Options (option to buy) | |
| Sybil Tasker | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2017 | 50,000 | 50,000 | - | - | Stock Options (option to buy) | |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.24 per share. | 24 Aug 2017 | 17,326 | 171,704 (1%) | 0% | 2.2 | 38,892 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.25 per share. | 24 Aug 2017 | 50,000 | 221,704 (1%) | 0% | 2.2 | 112,390 | Common Stock, par value $0.0001 |
| David J. Drutz | None | Purchase of securities on an exchange or from another person at price $ 2.15 per share. | 22 Aug 2017 | 5,000 | 25,777 (0%) | 0% | 2.2 | 10,758 | Common Stock, par value $0.0001 |
| David J. Drutz | None | Purchase of securities on an exchange or from another person at price $ 2.27 per share. | 22 Aug 2017 | 5,000 | 30,777 (0%) | 0% | 2.3 | 11,340 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.22 per share. | 21 Aug 2017 | 43,352 | 154,378 (0%) | 0% | 2.2 | 96,350 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.02 per share. | 21 Aug 2017 | 690 | 105,068 (0%) | 0% | 2.0 | 1,395 | Common Stock, par value $0.0001 |
| Derace L. Schaffer | None | Purchase of securities on an exchange or from another person at price $ 2.10 per share. | 21 Aug 2017 | 5,958 | 111,026 (0%) | 0% | 2.1 | 12,519 | Common Stock, par value $0.0001 |
| William J. Enright | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2017 | 71,644 | 0 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.08 per share. | 16 Aug 2017 | 71,644 | 89,431 (0%) | 0% | 0.1 | 5,732 | Common Stock |
| William J. Enright | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2017 | 91,733 | 0 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.08 per share. | 16 Aug 2017 | 91,733 | 181,164 (1%) | 0% | 0.1 | 7,339 | Common Stock |
| M. Scot Roberts | Chief Scientific Officer | Purchase of securities on an exchange or from another person at price $ 4.42 per share. | 06 Jun 2017 | 449 | 449 (0%) | 0% | 4.4 | 1,985 | Common Stock, par value $0.0001 |
| Sybil Tasker | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2017 | 40,000 | 40,000 | - | - | Stock Options (option to buy) | |
| John M. Gill | None | Purchase of securities on an exchange or from another person at price $ 4.34 per share. | 02 Jun 2017 | 1,000 | 83,224 (0%) | 0% | 4.3 | 4,344 | Common Stock, par value $0.0001 |
| David J. Drutz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 4,177 | 4,177 | - | - | Stock Option (option to buy) | |
| David J. Drutz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 20,777 | 20,777 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| David J. Drutz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 4,755 | 4,755 | - | - | Stock Option (option to buy) | |
| David J. Drutz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 1,791 | 1,791 | - | - | Stock Option (option to buy) | |
| David J. Drutz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 1,791 | 1,791 | - | - | Stock Option (option to buy) | |
| David J. Drutz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 2,090 | 2,090 | - | - | Stock Option (option to buy) | |
| David J. Drutz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 4,178 | 4,178 | - | - | Stock Option (option to buy) | |
| David J. Drutz | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 4,178 | 4,178 | - | - | Stock Option (option to buy) | |
| Elizabeth Czerepak | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 178,595 | 178,595 | - | - | Stock Option (option to buy) | |
| Elizabeth Czerepak | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 18,727 | 18,727 | - | - | Stock Option (option to buy) | |
| William J. Enright | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 71,644 | 71,644 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 91,733 | 91,733 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 183,347 | 183,347 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 99,927 | 99,927 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 125,887 | 125,887 | - | - | Stock Options (option to buy) | |
| William J. Enright | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 17,787 | 17,787 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 55,120 | 55,120 | - | - | Stock Option (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 11,235 | 11,235 | - | - | Stock Option (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 8,956 | 8,956 | - | - | Stock Option (option to buy) | |
| M. Scot Roberts | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 8,956 | 8,956 | - | - | Stock Option (option to buy) | |
| Sybil Tasker | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 48,691 | 48,691 | - | - | Stock Options (option to buy) | |
| Philip L. Hodges | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 4,455 | 4,455 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Philip L. Hodges | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 1,278,471 | 1,278,471 (1%) | 1% | 0 | Common Stock, par value $0.0001 | |
| Philip L. Hodges | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 36,785 | 36,785 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Klaus O. Schafer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 1,791 | 1,791 | - | - | Stock Option (option to buy) | |
| Klaus O. Schafer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 5,998 | 5,998 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Klaus O. Schafer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 4,775 | 4,775 | - | - | Stock Option (option to buy) | |
| Klaus O. Schafer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 1,791 | 1,791 | - | - | Stock Option (option to buy) | |
| Klaus O. Schafer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2017 | 1,791 | 1,791 | - | - | Stock Option (option to buy) | |
| Jeffrey W. Runge | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.11 per share. | 20 Jan 2017 | 20,000 | 197,700 (0%) | 0% | 3.1 | 62,200 | Common Stock, par value $0.0001 per share |
| Jeffrey W. Runge | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jan 2017 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Derace L. Schaffer | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2017 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Derace L. Schaffer | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.20 per share. | 13 Jan 2017 | 20,000 | 1,043,782 (1%) | 0% | 2.2 | 44,000 | Common Stock, $0.0001 par value per share |
| St Steven Peter | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2017 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| St Steven Peter | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2017 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| St Steven Peter | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.47 per share. | 04 Jan 2017 | 20,000 | 165,004 (0%) | 0% | 2.5 | 49,400 | Common Stock, par value $0.0001 per share |
| St Steven Peter | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.11 per share. | 04 Jan 2017 | 20,000 | 185,004 (0%) | 0% | 3.1 | 62,200 | Common Stock, par value $0.0001 per share |
| St Steven Peter | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.59 per share. | 04 Jan 2017 | 10,000 | 145,004 (0%) | 0% | 2.6 | 25,900 | Common Stock, par value $0.0001 per share |
| St Steven Peter | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2017 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| St Steven Peter | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.20 per share. | 04 Jan 2017 | 20,000 | 205,004 (0%) | 0% | 2.2 | 44,000 | Common Stock, par value $0.0001 per share |
| St Steven Peter | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2017 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Philip MacNeill | VP, CFO, Treasurer, Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2016 | 17,657 | 35,312 | - | - | Employee Stock Option (right to buy) | |
| Philip MacNeill | VP, CFO, Treasurer, Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2016 | 5,000 | 108,689 | - | - | Common Stock, par value $0.0001 per share | |
| Philip MacNeill | VP, CFO, Treasurer, Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2016 | 17,657 | 126,346 | - | - | Common Stock, par value $0.0001 per share | |
| Philip MacNeill | VP, CFO, Treasurer, Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2016 | 5,000 | 5,000 | - | - | Employee Stock Option (right to buy) | |
| Jeffrey W. Runge | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2016 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Jeffrey W. Runge | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2016 | 20,000 | 177,700 | - | - | Common Stock, par value $0.0001 per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 52,139 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 18,361 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 45,000 | - | - | Common Stock, $0.0001 par value per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 197,139 | - | - | Common Stock, $0.0001 par value per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 275,500 | - | - | Common Stock, $0.0001 par value per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 60,000 | 105,000 | - | - | Common Stock, $0.0001 par value per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 217,139 | - | - | Common Stock, $0.0001 par value per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 60,000 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 25,000 | - | - | Common Stock, $0.0001 par value per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 177,139 | - | - | Common Stock, $0.0001 par value per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 255,500 | - | - | Common Stock, $0.0001 par value per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 52,139 | 157,139 | - | - | Common Stock, $0.0001 par value per share | |
| Mitchel Sayare | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 18,361 | 235,500 | - | - | Common Stock, $0.0001 par value per share | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 37,500 | 0 | - | - | Stock Option (right to buy) | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 135,660 | 858,055 | - | - | Common Stock, $0.0001 par value per share | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 240,000 | 0 | - | - | Stock Option (right to buy) | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 30,573 | 444,895 | - | - | Common Stock, $0.0001 par value per share | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 878,055 | - | - | Common Stock, $0.0001 par value per share | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 30,573 | 0 | - | - | Stock Option (right to buy) | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 240,000 | 722,395 | - | - | Common Stock, $0.0001 par value per share | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 135,660 | 0 | - | - | Stock option (right to buy) | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 37,500 | 482,395 | - | - | Common Stock, $0.0001 par value per share | |
| Eric I. Richman | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 20,000 | 898,055 | - | - | Common Stock, $0.0001 par value per share | |
| John Gill | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 100,000 | 822,244 | - | - | Common Stock, $0.0001 par value per share | |
| John Gill | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2016 | 100,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Derace L. Schaffer | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Derace L. Schaffer | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2016 | 20,000 | 0 | - | - | Stock option (right to buy) | |
| Derace L. Schaffer | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2016 | 20,000 | 963,782 | - | - | Common Stock, $0.0001 par value per share | |
| Derace L. Schaffer | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Sep 2016 | 20,000 | 0 | - | - | Stock option (right to buy) |